<p>Sino Biopharmaceutical Limited announced positive results from a Phase II clinical trial of TQA3605, a core protein allosteric modulator (CpAM) for the treatment of chronic hepatitis B. The randomized, double-blind, placebo-controlled, multi-center study evaluated the efficacy and safety of TQA3605 in combination with nucleos(t) ide analogues (NAs) in patients with chronic HBV infection and low-level viremia. A total of 122 subjects were enrolled, and the results showed that all TQA3605 dose groups achieved approximately 90% of subjects with HBV DNA levels below the lower limit of quantification (&lt;20 IU/mL), significantly surpassing the NAs monotherapy control group. The safety profile of TQA3605 was generally favorable, with most adverse events reported as Grade 1 to 2 and comparable incidence rates to the control group. The company stated that detailed results from the study will be presented at upcoming international academic conferences. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sino Biopharmaceutical Limited published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260127-12002053), on January 27, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

<p>Sino Biopharmaceutical Limited reported positive Phase II trial results for TQA3605, a treatment for chronic hepatitis B. The study involved 122 patients and showed that approximately 90% of those receiving TQA3605 had HBV DNA levels below 20 IU/mL, outperforming the control group on nucleos(t) ide analogues. The safety profile was favorable, with most adverse events being mild. Detailed results will be shared at upcoming international conferences. This news is for informational purposes only and should not be considered financial or legal advice.</p>

Reuters

Guotai CSI Bio-medicine ETF

China Universal 800 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

E Fund CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

ChinaAMC CSI Biotechnology Theme ETF

SINO BIOPHARM

Yinhua CSI Research Sector 100 ETF

Minsheng Royal CSI Biotechnology Theme ETF

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Yinhua CSI Innovative Drugs Industry ETF

China Merchants CSI Biotechnology Theme ETF

ChinaAMC SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP CSI Pharmaceuticals ETF

Sino Biopharmaceutical Reports Positive Phase II Results for Hepatitis B Drug TQA3605